首页 > 最新文献

Cardiovascular & hematological agents in medicinal chemistry最新文献

英文 中文
Comparison between the ECG Outcomes of Metoprolol and Bisoprolol. 美托洛尔和比索洛尔心电图结果的比较。
Pub Date : 2024-01-01 DOI: 10.2174/0118715257252349231018151957
Ahmad Abdulrahman Almeman, Yousef Obaid Alharbi, Abdulaziz Sulaiman Alwahhabi, Abdulaziz Abdullah Almutairi, Moayad Yousef Alnasr, Abdulrahaman Almesnid

Background: Beta-blockers are essential agents in the management of cardiovascular diseases, such as heart failure, acute myocardial infarction (MI), and cardiac arrhythmias. However, there are diurnal variations in the cardioprotective effects of the subgroups as a result of their different pharmacokinetic, pharmacodynamic, and pharmacogenetic profiles.

Objectives: We aimed to compare metoprolol and bisoprolol in terms of electrocardiogram (ECG) outcomes.

Methods: A retrospective cross-sectional study was conducted at Prince Sultan Cardiac Center. The trial included 404 patients who met the inclusion criteria (204 in the metoprolol arm and 200 in the bisoprolol arm). Using case record forms that had already been created, information, such as patient demographics, medical histories, and treatment histories, was taken from their medical files. The most recent ECG records were also gathered. The ethical approval for this study was obtained from Qassim ethical committee (approval number: 45-44-902).

Results: There was no significant difference found between the patients in both arms in terms of baseline characteristics, age, or sex.

Conclusion: In this retrospective cross-sectional study, we have compared the effects of metoprolol and bisoprolol beta blockers on ECG changes. The findings have indicated no difference between metoprolol and bisoprolol groups in terms of all ECG readings, particularly PR/ms, QTC-ms, and ventricular rate. Further studies are required to confirm these findings.

背景:β受体阻滞剂是治疗心血管疾病的重要药物,如心力衰竭、急性心肌梗死和心律失常。然而,由于不同的药代动力学、药效学和药物遗传学特征,亚组的心脏保护作用存在昼夜变化。目的:我们旨在比较美托洛尔和比索洛尔在心电图(ECG)方面的结果。方法:在苏丹王子心脏中心进行回顾性横断面研究。该试验包括404名符合纳入标准的患者(美托洛尔组204名,比索洛尔组200名)。使用已经创建的病例记录表,从他们的医疗档案中获取患者人口统计、病史和治疗史等信息。还收集了最近的心电图记录。本研究获得了Qassim伦理委员会的伦理批准(批准号:45-44-902)。结果:两组患者在基线特征、年龄或性别方面没有发现显著差异。结论:在这项回顾性横断面研究中,我们比较了美托洛尔和比索洛尔β受体阻滞剂对心电图变化的影响。研究结果表明,美托洛尔组和比索洛尔组在所有心电图读数,特别是PR/ms、QTC ms和心室率方面没有差异。需要进一步的研究来证实这些发现。
{"title":"Comparison between the ECG Outcomes of Metoprolol and Bisoprolol.","authors":"Ahmad Abdulrahman Almeman, Yousef Obaid Alharbi, Abdulaziz Sulaiman Alwahhabi, Abdulaziz Abdullah Almutairi, Moayad Yousef Alnasr, Abdulrahaman Almesnid","doi":"10.2174/0118715257252349231018151957","DOIUrl":"10.2174/0118715257252349231018151957","url":null,"abstract":"<p><strong>Background: </strong>Beta-blockers are essential agents in the management of cardiovascular diseases, such as heart failure, acute myocardial infarction (MI), and cardiac arrhythmias. However, there are diurnal variations in the cardioprotective effects of the subgroups as a result of their different pharmacokinetic, pharmacodynamic, and pharmacogenetic profiles.</p><p><strong>Objectives: </strong>We aimed to compare metoprolol and bisoprolol in terms of electrocardiogram (ECG) outcomes.</p><p><strong>Methods: </strong>A retrospective cross-sectional study was conducted at Prince Sultan Cardiac Center. The trial included 404 patients who met the inclusion criteria (204 in the metoprolol arm and 200 in the bisoprolol arm). Using case record forms that had already been created, information, such as patient demographics, medical histories, and treatment histories, was taken from their medical files. The most recent ECG records were also gathered. The ethical approval for this study was obtained from Qassim ethical committee (approval number: 45-44-902).</p><p><strong>Results: </strong>There was no significant difference found between the patients in both arms in terms of baseline characteristics, age, or sex.</p><p><strong>Conclusion: </strong>In this retrospective cross-sectional study, we have compared the effects of metoprolol and bisoprolol beta blockers on ECG changes. The findings have indicated no difference between metoprolol and bisoprolol groups in terms of all ECG readings, particularly PR/ms, QTC-ms, and ventricular rate. Further studies are required to confirm these findings.</p>","PeriodicalId":93924,"journal":{"name":"Cardiovascular & hematological agents in medicinal chemistry","volume":" ","pages":"503-507"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71430166","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Endothelial Cell Aging and Autophagy Dysregulation. 内皮细胞老化与自噬失调
Pub Date : 2024-01-01 DOI: 10.2174/0118715257275690231129101408
Basheer Abdullah Marzoog

Entropy is a natural process that affects all living cells, including senescence, an irreversible physiological process that impairs cell homeostasis. Age is a significant factor in disease development, and the pathogenesis of endothelial cell aging is multifactorial. Autophagy dysfunction accelerates endothelial cell aging and cell death, while autophagy preserves endothelial cell youthfulness through intracellular homeostasis and gene expression regulation. Sirt, mTORC1, and AMPK are youthfulness genes that induce autophagy by inhibiting mTOR and upregulating FIP200/Atg13/ULK1. Aged endothelial cells have decreased levels of Lamin B1, γH2AX, Ki67, BrdU, PCNA, and SA β-Gal. Maintaining healthy young endothelial cells can prevent most cardiovascular diseases. Autophagy targeting is a potential future therapeutic strategy to modify endothelial cell age and potentially slow or reverse the aging process. This article provides state-of-the-art research on the role of autophagy in endothelial cell aging. Hypothesizing that autophagy dysregulation is associated with early endothelial cell dysfunction and further clinical sequelae, including atherosclerosis formation, leading to various cardiovascular diseases.

熵是一个影响所有活细胞的自然过程,包括衰老,衰老是一个不可逆转的生理过程,会损害细胞的平衡。年龄是疾病发生的一个重要因素,而内皮细胞衰老的发病机制是多因素的。自噬功能障碍会加速内皮细胞衰老和细胞死亡,而自噬则通过细胞内平衡和基因表达调控来保持内皮细胞的年轻状态。Sirt、mTORC1 和 AMPK 是青春基因,它们通过抑制 mTOR 和上调 FIP200/Atg13/ULK1 来诱导自噬。衰老的内皮细胞中 Lamin B1、γH2AX、Ki67、BrdU、PCNA 和 SA β-Gal 的水平下降。 保持健康年轻的内皮细胞可以预防大多数心血管疾病。以自噬为靶点是未来改变内皮细胞年龄、延缓或逆转衰老过程的潜在治疗策略。本文介绍了有关自噬在内皮细胞衰老中作用的最新研究。假设自噬失调与早期内皮细胞功能障碍和进一步的临床后遗症(包括动脉粥样硬化的形成)有关,从而导致各种心血管疾病。
{"title":"Endothelial Cell Aging and Autophagy Dysregulation.","authors":"Basheer Abdullah Marzoog","doi":"10.2174/0118715257275690231129101408","DOIUrl":"10.2174/0118715257275690231129101408","url":null,"abstract":"<p><p>Entropy is a natural process that affects all living cells, including senescence, an irreversible physiological process that impairs cell homeostasis. Age is a significant factor in disease development, and the pathogenesis of endothelial cell aging is multifactorial. Autophagy dysfunction accelerates endothelial cell aging and cell death, while autophagy preserves endothelial cell youthfulness through intracellular homeostasis and gene expression regulation. Sirt, mTORC1, and AMPK are youthfulness genes that induce autophagy by inhibiting mTOR and upregulating FIP200/Atg13/ULK1. Aged endothelial cells have decreased levels of Lamin B1, γH2AX, Ki67, BrdU, PCNA, and SA β-Gal. Maintaining healthy young endothelial cells can prevent most cardiovascular diseases. Autophagy targeting is a potential future therapeutic strategy to modify endothelial cell age and potentially slow or reverse the aging process. This article provides state-of-the-art research on the role of autophagy in endothelial cell aging. Hypothesizing that autophagy dysregulation is associated with early endothelial cell dysfunction and further clinical sequelae, including atherosclerosis formation, leading to various cardiovascular diseases.</p>","PeriodicalId":93924,"journal":{"name":"Cardiovascular & hematological agents in medicinal chemistry","volume":" ","pages":"413-420"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139543752","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lipotoxicity, ER Stress, and Cardiovascular Disease: Current Understanding and Future Directions. 脂毒性、内质网应激和心血管疾病:目前的理解和未来的方向。
Pub Date : 2024-01-01 DOI: 10.2174/0118715257262366230928051902
Smriti Shreya, Md Jahangir Alam, Anupriya, Saumya Jaiswal, Vibha Rani, Buddhi Prakash Jain

The endoplasmic reticulum (ER) is a sub-cellular organelle that is responsible for the correct folding of proteins, lipid biosynthesis, calcium storage, and various post-translational modifications. In the disturbance of ER functioning, unfolded or misfolded proteins accumulate inside the ER lumen and initiate downstream signaling called unfolded protein response (UPR). The UPR signaling pathway is involved in lipolysis, triacylglycerol synthesis, lipogenesis, the mevalonate pathway, and low-density lipoprotein receptor recycling. ER stress also affects lipid metabolism by changing the levels of enzymes that are involved in the synthesis or modifications of lipids and causing lipotoxicity. Lipid metabolism and cardiac diseases are in close association as the deregulation of lipid metabolism leads to the development of various cardiovascular diseases (CVDs). Several studies have suggested that lipotoxicity is one of the important factors for cardiovascular disorders. In this review, we will discuss how ER stress affects lipid metabolism and their interplay in the development of cardiovascular disorders. Further, the current therapeutics available to target ER stress and lipid metabolism in various CVDs will be summarized.

内质网(ER)是一种亚细胞器,负责蛋白质的正确折叠、脂质生物合成、钙储存和各种翻译后修饰。在ER功能紊乱的过程中,未折叠或错误折叠的蛋白质积聚在ER腔内,并启动下游信号传导,称为未折叠蛋白质反应(UPR)。UPR信号通路参与脂解、三酰甘油合成、脂肪生成、甲羟戊酸途径和低密度脂蛋白受体循环。内质网应激还通过改变参与脂质合成或修饰的酶的水平来影响脂质代谢,并导致脂毒性。脂质代谢与心脏病密切相关,因为脂质代谢的失调会导致各种心血管疾病的发展。几项研究表明,脂毒性是心血管疾病的重要因素之一。在这篇综述中,我们将讨论内质网应激如何影响脂质代谢及其在心血管疾病发展中的相互作用。此外,将总结目前可用于靶向各种心血管疾病的ER应激和脂质代谢的治疗方法。
{"title":"Lipotoxicity, ER Stress, and Cardiovascular Disease: Current Understanding and Future Directions.","authors":"Smriti Shreya, Md Jahangir Alam, Anupriya, Saumya Jaiswal, Vibha Rani, Buddhi Prakash Jain","doi":"10.2174/0118715257262366230928051902","DOIUrl":"10.2174/0118715257262366230928051902","url":null,"abstract":"<p><p>The endoplasmic reticulum (ER) is a sub-cellular organelle that is responsible for the correct folding of proteins, lipid biosynthesis, calcium storage, and various post-translational modifications. In the disturbance of ER functioning, unfolded or misfolded proteins accumulate inside the ER lumen and initiate downstream signaling called unfolded protein response (UPR). The UPR signaling pathway is involved in lipolysis, triacylglycerol synthesis, lipogenesis, the mevalonate pathway, and low-density lipoprotein receptor recycling. ER stress also affects lipid metabolism by changing the levels of enzymes that are involved in the synthesis or modifications of lipids and causing lipotoxicity. Lipid metabolism and cardiac diseases are in close association as the deregulation of lipid metabolism leads to the development of various cardiovascular diseases (CVDs). Several studies have suggested that lipotoxicity is one of the important factors for cardiovascular disorders. In this review, we will discuss how ER stress affects lipid metabolism and their interplay in the development of cardiovascular disorders. Further, the current therapeutics available to target ER stress and lipid metabolism in various CVDs will be summarized.</p>","PeriodicalId":93924,"journal":{"name":"Cardiovascular & hematological agents in medicinal chemistry","volume":" ","pages":"319-335"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49686260","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Study of the Antihypertensive Effect of Scorzonera undulata ssp. deliciosa in Albino Wistar Rats. 白化Wistar大鼠体内Scorzonera undulata ssp. deliciosa的降压效果研究
Pub Date : 2024-01-01 DOI: 10.2174/0118715257243190231024164358
Ayoub Amssayef, Mohammed Ajebli, Mohamed Eddouks

Aims: The study aimed to investigate the antihypertensive activity of Scorzonera undulata ssp. deliciosa.

Background: Scorzonera undulata ssp deliciosa, locally known as "Guiz", is used in traditional medicine in Morocco as a diuretic and mainly against snake bites.

Objectives: This study investigated the possible antihypertensive effect of the aqueous extract of Scorzonera undulata (AESU).

Materials and methods: In the present study, the antihypertensive activity of AESU was tested in normotensive and hypertensive rats Results: The results indicated that AESU decreased the systolic, diastolic, and mean arterial blood pressure in hypertensive rats. The data revealed that AESU exerted its antihypertensive effect through vasodilatory properties. Interestingly, the study demonstrated that the vasorelaxation ability of AESU might be mediated through receptor-operated calcium channels (ROCCs). However, AESU dhad effect on inhibiting ACE-2.

Conclusion: The present study indicates the antihypertensive and vasorelaxant activities of AESU in hypertensive rats.

研究目的:本研究旨在探讨 Scorzonera undulata ssp. deliciosa 的降压活性:背景:Scorzonera undulata ssp deliciosa 在当地被称为 "Guiz",在摩洛哥的传统医学中被用作利尿剂,主要用于治疗蛇咬伤:材料与方法:本研究调查了未落叶山苍子水提取物(AESU)可能具有的降压作用:本研究在正常血压大鼠和高血压大鼠中测试了 AESU AUSU 的抗高血压活性:结果表明,AESU 能降低高血压大鼠的收缩压、舒张压和平均动脉血压。数据显示,AESU 通过扩张血管的特性发挥降压作用。有趣的是,研究表明 AESU 的血管舒张能力可能是通过受体操作钙通道(ROCCs)介导的。然而,AESU 对抑制 ACE-2 也有作用:本研究表明,AESU 对高血压大鼠具有降压和舒张血管的活性。
{"title":"Study of the Antihypertensive Effect of <i>Scorzonera undulata</i> ssp. deliciosa in Albino Wistar Rats.","authors":"Ayoub Amssayef, Mohammed Ajebli, Mohamed Eddouks","doi":"10.2174/0118715257243190231024164358","DOIUrl":"10.2174/0118715257243190231024164358","url":null,"abstract":"<p><strong>Aims: </strong>The study aimed to investigate the antihypertensive activity of <i>Scorzonera undulata</i> ssp. deliciosa.</p><p><strong>Background: </strong><i>Scorzonera undulata</i> ssp <i>deliciosa</i>, locally known as \"<i>Guiz</i>\", is used in traditional medicine in Morocco as a diuretic and mainly against snake bites.</p><p><strong>Objectives: </strong>This study investigated the possible antihypertensive effect of the aqueous extract of <i>Scorzonera undulata</i> (AESU).</p><p><strong>Materials and methods: </strong>In the present study, the antihypertensive activity of AESU was tested in normotensive and hypertensive rats Results: The results indicated that AESU decreased the systolic, diastolic, and mean arterial blood pressure in hypertensive rats. The data revealed that AESU exerted its antihypertensive effect through vasodilatory properties. Interestingly, the study demonstrated that the vasorelaxation ability of AESU might be mediated through receptor-operated calcium channels (ROCCs). However, AESU dhad effect on inhibiting ACE-2.</p><p><strong>Conclusion: </strong>The present study indicates the antihypertensive and vasorelaxant activities of AESU in hypertensive rats.</p>","PeriodicalId":93924,"journal":{"name":"Cardiovascular & hematological agents in medicinal chemistry","volume":" ","pages":"159-167"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138811267","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy of Dyslipidemia Control by Combination Therapy with Rosuvastatin 10 Mg and Ezetimibe 10 Mg Compared with Rosuvastatin 20 Mg Monotherapy in Patients with Chronic Coronary Syndromes: A Randomized, Single-blind Controlled Trial. 与瑞舒伐他汀 20 毫克单药治疗相比,瑞舒伐他汀 10 毫克和依折麦布 10 毫克联合治疗对慢性冠状动脉综合征患者控制血脂异常的疗效:一项随机、单盲对照试验。
Pub Date : 2024-01-01 DOI: 10.2174/0118715257274373231211060714
An Viet Tran, Bao Lam Thai Tran, Nghia Minh Bui, Anh To Tan Le, Diem Thi Nguyen, Son Kim Tran, Toan Hoang Ngo

Background: Studies have shown the combination treatment effectiveness of using rosuvastatin and ezetimibe in patients with chronic coronary artery disease. Our study aim to evaluate the effectiveness of dyslipidemia treatment with the combination of rosuvastatin and ezetimibe 10mg in patients with chronic coronary artery disease compared with 20 mg rosuvastatin.

Objectives: To evaluate the effectiveness of dyslipidemia treatment with the target of LDL-c < 1.4 mmol/L between combination therapy with rosuvastatin 10 mg and ezetimibe 10 mg in patients with chronic coronary artery disease compared with monotherapy increasing the dose of rosuvastatin 20 mg in Vietnam.

Methods: A randomized controlled clinical trial, single-blind, parallel-group with a 1:1 randomized ratio in 103 outpatients with chronic coronary syndromes treated with rosuvastatin 10mg daily. Group A received the combination therapy with rosuvastatin 10 mg plus ezetimibe 10 mg daily, and group B received rosuvastatin 20 mg daily. The primary outcome was to assess the efficacy of low-density lipoprotein - cholesterol (LDL-c) control between rosuvastatin 10 mg plus ezetimibe 10 mg versus rosuvastatin 20 mg after 4 weeks and 8 weeks.

Results: After 8 weeks of intervention, the proportion of archived treatment target patients with LDL-c < 1.4 mmol/L in groups A and B was 69.2% and 44.2%, respectively (Risk ratio (RR) = 1.57, p < 0.01), 50% LDL reduction was 27.9% and 55.8%, respectively (RR = 2.00, p < 0.01), and archived both targets were 51.9% and 25.6% (RR = 2.03, p < 0.01).

Conclusion: Group A's LDL-c reduction effect and target achievement proportion (Rosuvastatin 10mg + Ezetimibe 10 mg) were significantly higher than Group B's (Rosuvastatin 20 mg). Both medication therapies were safe in patients, and the increased dose of monotherapy showed more side effects than the combination therapy.

背景:研究表明,慢性冠心病患者使用罗伐他汀和依折麦布联合治疗效果显著。我们的研究旨在评估罗伐他汀和依折麦布 10 毫克联合治疗慢性冠心病患者血脂异常的疗效,并与罗伐他汀 20 毫克进行比较:评估越南慢性冠心病患者使用罗伐他汀10毫克和依折麦布10毫克联合疗法与增加罗伐他汀20毫克剂量的单一疗法治疗以LDL-c<1.4毫摩尔/升为目标的血脂异常的有效性:随机对照临床试验,单盲,平行组,随机比例为1:1,103名慢性冠状动脉综合征门诊患者每天接受罗伐他汀10毫克治疗。A 组每天服用罗伐他汀 10 毫克加依折麦布 10 毫克的联合疗法,B 组每天服用罗伐他汀 20 毫克。主要结果是评估罗伐他汀10毫克加依折麦布10毫克与罗伐他汀20毫克在4周和8周后控制低密度脂蛋白胆固醇(LDL-c)的疗效:干预8周后,A组和B组LDL-c<1.4 mmol/L的存档治疗目标患者比例分别为69.2%和44.2%(风险比(RR)=1.57,P<0.01),LDL降低50%的患者比例分别为27.9%和55.8%(RR=2.00,P<0.01),存档治疗目标患者比例分别为51.9%和25.6%(RR=2.03,P<0.01):结论:A组(瑞舒伐他汀10毫克+依折麦布10毫克)的低密度脂蛋白胆固醇降低效果和达标率明显高于B组(瑞舒伐他汀20毫克)。两种药物疗法对患者都是安全的,增加剂量的单一疗法比联合疗法的副作用更大。
{"title":"Efficacy of Dyslipidemia Control by Combination Therapy with Rosuvastatin 10 Mg and Ezetimibe 10 Mg Compared with Rosuvastatin 20 Mg Monotherapy in Patients with Chronic Coronary Syndromes: A Randomized, Single-blind Controlled Trial.","authors":"An Viet Tran, Bao Lam Thai Tran, Nghia Minh Bui, Anh To Tan Le, Diem Thi Nguyen, Son Kim Tran, Toan Hoang Ngo","doi":"10.2174/0118715257274373231211060714","DOIUrl":"10.2174/0118715257274373231211060714","url":null,"abstract":"<p><strong>Background: </strong>Studies have shown the combination treatment effectiveness of using rosuvastatin and ezetimibe in patients with chronic coronary artery disease. Our study aim to evaluate the effectiveness of dyslipidemia treatment with the combination of rosuvastatin and ezetimibe 10mg in patients with chronic coronary artery disease compared with 20 mg rosuvastatin.</p><p><strong>Objectives: </strong>To evaluate the effectiveness of dyslipidemia treatment with the target of LDL-c < 1.4 mmol/L between combination therapy with rosuvastatin 10 mg and ezetimibe 10 mg in patients with chronic coronary artery disease compared with monotherapy increasing the dose of rosuvastatin 20 mg in Vietnam.</p><p><strong>Methods: </strong>A randomized controlled clinical trial, single-blind, parallel-group with a 1:1 randomized ratio in 103 outpatients with chronic coronary syndromes treated with rosuvastatin 10mg daily. Group A received the combination therapy with rosuvastatin 10 mg plus ezetimibe 10 mg daily, and group B received rosuvastatin 20 mg daily. The primary outcome was to assess the efficacy of low-density lipoprotein - cholesterol (LDL-c) control between rosuvastatin 10 mg plus ezetimibe 10 mg versus rosuvastatin 20 mg after 4 weeks and 8 weeks.</p><p><strong>Results: </strong>After 8 weeks of intervention, the proportion of archived treatment target patients with LDL-c < 1.4 mmol/L in groups A and B was 69.2% and 44.2%, respectively (Risk ratio (RR) = 1.57, p < 0.01), 50% LDL reduction was 27.9% and 55.8%, respectively (RR = 2.00, p < 0.01), and archived both targets were 51.9% and 25.6% (RR = 2.03, p < 0.01).</p><p><strong>Conclusion: </strong>Group A's LDL-c reduction effect and target achievement proportion (Rosuvastatin 10mg + Ezetimibe 10 mg) were significantly higher than Group B's (Rosuvastatin 20 mg). Both medication therapies were safe in patients, and the increased dose of monotherapy showed more side effects than the combination therapy.</p>","PeriodicalId":93924,"journal":{"name":"Cardiovascular & hematological agents in medicinal chemistry","volume":" ","pages":"390-398"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139565310","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Salivary Biomarkers for Oral Cancer Detection: Insights from Human DNA and RNA Analysis. 用于口腔癌检测的唾液生物标记物:人类 DNA 和 RNA 分析的启示。
Pub Date : 2024-01-01 DOI: 10.2174/0118715257269271231201094946
Archana Navale, Atharva Deshpande

Oral cancer is a significant global health concern, with a high mortality rate mainly due to late-stage diagnosis. Early detection plays a critical role in improving patient outcomes, highlighting the need for non-invasive and accessible screening methods. Salivary biomarkers have emerged as a promising avenue for oral cancer detection, leveraging advancements in human DNA and RNA analysis. Several DNA-based biomarkers, such as genetic mutations, chromosomal aberrations, and epigenetic alterations, have shown promise in detecting oral cancer at various stages. Likewise, RNA-based biomarkers, including microRNAs, long non-coding RNAs, and messenger RNAs, have demonstrated potential for diagnosing oral cancer and predicting treatment outcomes. The integration of high-throughput sequencing technologies, such as next-generation sequencing and transcriptomic profiling, has enabled the identification of novel biomarkers and provided deeper insights into the molecular mechanisms underlying oral cancer development and progression. Despite the promising results, challenges remain in standardizing sample collection, establishing robust biomarker panels, and validating their clinical utility. Nevertheless, salivary biomarkers hold great promise as a non-invasive, cost-effective, and accessible approach for oral cancer detection, ultimately leading to improved patient outcomes through early diagnosis and intervention. The analysis of genetic material obtained from saliva offers several advantages, including ease of collection, non-invasiveness, and the potential for repeated sampling. Furthermore, saliva reflects the physiological and pathological status of the oral cavity, making it an ideal source for biomarker discovery and validation. This article presents a comprehensive review of the current research on salivary biomarkers for oral cancer detection, focusing on insights gained from human DNA and RNA analysis.

口腔癌是全球关注的重大健康问题,死亡率高主要是由于晚期诊断所致。早期检测在改善患者预后方面起着至关重要的作用,这就凸显了对非侵入性和可获得性筛查方法的需求。唾液生物标记物利用人类 DNA 和 RNA 分析技术的进步,已成为口腔癌检测的一个有前途的途径。一些基于 DNA 的生物标记物,如基因突变、染色体畸变和表观遗传学改变,已显示出在不同阶段检测口腔癌的前景。同样,基于 RNA 的生物标志物,包括微 RNA、长非编码 RNA 和信使 RNA,也显示出诊断口腔癌和预测治疗效果的潜力。下一代测序和转录组分析等高通量测序技术的整合使新型生物标志物的鉴定成为可能,并为口腔癌的发生和发展的分子机制提供了更深入的见解。尽管取得了令人鼓舞的成果,但在样本采集标准化、建立健全的生物标志物面板以及验证其临床效用方面仍存在挑战。尽管如此,唾液生物标志物作为一种非侵入性、经济高效且易于获取的口腔癌检测方法,仍具有广阔的前景,最终可通过早期诊断和干预改善患者的预后。对从唾液中获取的遗传物质进行分析具有多种优势,包括易于收集、无创伤以及可重复采样。此外,唾液还能反映口腔的生理和病理状态,是发现和验证生物标记物的理想来源。本文全面回顾了目前用于口腔癌检测的唾液生物标记物研究,重点介绍了从人类 DNA 和 RNA 分析中获得的见解。
{"title":"Salivary Biomarkers for Oral Cancer Detection: Insights from Human DNA and RNA Analysis.","authors":"Archana Navale, Atharva Deshpande","doi":"10.2174/0118715257269271231201094946","DOIUrl":"10.2174/0118715257269271231201094946","url":null,"abstract":"<p><p>Oral cancer is a significant global health concern, with a high mortality rate mainly due to late-stage diagnosis. Early detection plays a critical role in improving patient outcomes, highlighting the need for non-invasive and accessible screening methods. Salivary biomarkers have emerged as a promising avenue for oral cancer detection, leveraging advancements in human DNA and RNA analysis. Several DNA-based biomarkers, such as genetic mutations, chromosomal aberrations, and epigenetic alterations, have shown promise in detecting oral cancer at various stages. Likewise, RNA-based biomarkers, including microRNAs, long non-coding RNAs, and messenger RNAs, have demonstrated potential for diagnosing oral cancer and predicting treatment outcomes. The integration of high-throughput sequencing technologies, such as next-generation sequencing and transcriptomic profiling, has enabled the identification of novel biomarkers and provided deeper insights into the molecular mechanisms underlying oral cancer development and progression. Despite the promising results, challenges remain in standardizing sample collection, establishing robust biomarker panels, and validating their clinical utility. Nevertheless, salivary biomarkers hold great promise as a non-invasive, cost-effective, and accessible approach for oral cancer detection, ultimately leading to improved patient outcomes through early diagnosis and intervention. The analysis of genetic material obtained from saliva offers several advantages, including ease of collection, non-invasiveness, and the potential for repeated sampling. Furthermore, saliva reflects the physiological and pathological status of the oral cavity, making it an ideal source for biomarker discovery and validation. This article presents a comprehensive review of the current research on salivary biomarkers for oral cancer detection, focusing on insights gained from human DNA and RNA analysis.</p>","PeriodicalId":93924,"journal":{"name":"Cardiovascular & hematological agents in medicinal chemistry","volume":" ","pages":"249-257"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139565315","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Combined Administration of Metformin and Vitamin D: A Futuristic Approach for Management of Hyperglycemia. 二甲双胍和维生素D联合用药:治疗高血糖的未来方法。
Pub Date : 2024-01-01 DOI: 10.2174/0118715257261643231018102928
Sakshi Tyagi, Shalini Mani

Diabetes is a series of metabolic disorders that can be categorized into three types depending on different aspects associated with age at onset, intensity of insulin resistance, and beta- cell dysfunction: Type 1 and 2 Diabetes, and Gestational Diabetes Mellitus. Type 2 Diabetes Mellitus (T2DM) has recently been found to account for more than 85% of diabetic cases. The current review intends to raise awareness among clinicians/researchers that combining vitamin D3 with metformin may pave the way for better T2DM treatment and management. An extensive literature survey was performed to analyze vitamin D's role in regulating insulin secretion, their action on the target cells and thus maintaining the normal glucose level. On the other side, the anti-hyperglycemic effect of metformin as well as its detailed mechanism of action was also studied. Interestingly both compounds are known to exhibit the antioxidant effect too. Literature supporting the correlation between diabetic phenotypes and deficiency of vitamin D was also explored further. To thoroughly understand the common/overlapping pathways responsible for the antidiabetic as well as antioxidant nature of metformin and vitamin D3, we compared their antihyperglycemic and antioxidant activities. With this background, we are proposing the hypothesis that it would be of great interest if these two compounds could work in synergy to better manage the condition of T2DM and associated disorders.

糖尿病是一系列代谢紊乱,根据发病年龄、胰岛素抵抗强度和β细胞功能障碍的不同方面,可分为三类:1型和2型糖尿病,以及妊娠期糖尿病。2型糖尿病(T2DM)最近被发现占糖尿病病例的85%以上。目前的综述旨在提高临床医生/研究人员的认识,即将维生素D3与二甲双胍相结合可能为更好的T2DM治疗和管理铺平道路。进行了一项广泛的文献调查,以分析维生素D在调节胰岛素分泌中的作用,它们对靶细胞的作用,从而维持正常的葡萄糖水平。另一方面,还研究了二甲双胍的抗高血糖作用及其详细的作用机制。有趣的是,已知这两种化合物也具有抗氧化作用。支持糖尿病表型与维生素D缺乏之间相关性的文献也被进一步探索。为了彻底了解二甲双胍和维生素D3抗糖尿病和抗氧化的共同/重叠途径,我们比较了它们的抗高血糖和抗氧化活性。在这种背景下,我们提出了一个假设,即如果这两种化合物能够协同作用,更好地控制T2DM和相关疾病的病情,这将是非常令人感兴趣的。
{"title":"Combined Administration of Metformin and Vitamin D: A Futuristic Approach for Management of Hyperglycemia.","authors":"Sakshi Tyagi, Shalini Mani","doi":"10.2174/0118715257261643231018102928","DOIUrl":"10.2174/0118715257261643231018102928","url":null,"abstract":"<p><p>Diabetes is a series of metabolic disorders that can be categorized into three types depending on different aspects associated with age at onset, intensity of insulin resistance, and beta- cell dysfunction: Type 1 and 2 Diabetes, and Gestational Diabetes Mellitus. Type 2 Diabetes Mellitus (T2DM) has recently been found to account for more than 85% of diabetic cases. The current review intends to raise awareness among clinicians/researchers that combining vitamin D3 with metformin may pave the way for better T2DM treatment and management. An extensive literature survey was performed to analyze vitamin D's role in regulating insulin secretion, their action on the target cells and thus maintaining the normal glucose level. On the other side, the anti-hyperglycemic effect of metformin as well as its detailed mechanism of action was also studied. Interestingly both compounds are known to exhibit the antioxidant effect too. Literature supporting the correlation between diabetic phenotypes and deficiency of vitamin D was also explored further. To thoroughly understand the common/overlapping pathways responsible for the antidiabetic as well as antioxidant nature of metformin and vitamin D3, we compared their antihyperglycemic and antioxidant activities. With this background, we are proposing the hypothesis that it would be of great interest if these two compounds could work in synergy to better manage the condition of T2DM and associated disorders.</p>","PeriodicalId":93924,"journal":{"name":"Cardiovascular & hematological agents in medicinal chemistry","volume":" ","pages":"258-275"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71490019","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Antihypertensive and ACE-2 Inhibitory Effects of Daphne gnidium in Rats. Daphne gnidium 对大鼠的降压和 ACE-2 抑制作用
Pub Date : 2024-01-01 DOI: 10.2174/0118715257251651231212045407
Ismail Bouadid, Adil Qabouche, Mohamed Eddouks

Aims: The antihypertensive activity of Daphne gnidium was tested.

Background: Daphne gnidium (Thymelaeaceae) is used against hypertension.

Objective: The antihypertensive effect of Daphne gnidium was evaluated in this study.

Methods: The effect of Daphne gnidium aqueous extract (DGAE, 100 and 180 mg/kg) on blood pressure was evaluated in rats. In addition, the vasorelaxant effect of this extract was also tested.

Results: DGAE lowered blood pressure in hypertensive rats and exhibited vasorelaxant activity. In addition, cumulative concentrations of DGAE induced vasodilatation through receptoractivated calcium channels (ROCCs) without affecting ACE-2.

Conclusion: The aqueous extract of Daphne gnidium exhibits antihypertensive activity and induces vasodilatation via the inhibition of Ca2+ entry.

目的:测试水飞蓟的抗高血压活性:背景:Daphne gnidium(百日草科)可用于治疗高血压:本研究评估了钩藤的降压作用:方法:评估钩藤水提取物(DGAE,100 和 180 mg/kg)对大鼠血压的影响。此外,还测试了该提取物的血管舒张作用:结果:DGAE 可降低高血压大鼠的血压,并具有舒张血管的活性。此外,DGAE 的累积浓度可通过受体激活钙通道(ROCCs)诱导血管扩张,而不会影响 ACE-2:结论:Daphne gnidium 的水提取物具有抗高血压活性,并能通过抑制 Ca2+ 进入诱导血管扩张。
{"title":"Antihypertensive and ACE-2 Inhibitory Effects of <i>Daphne gnidium</i> in Rats.","authors":"Ismail Bouadid, Adil Qabouche, Mohamed Eddouks","doi":"10.2174/0118715257251651231212045407","DOIUrl":"10.2174/0118715257251651231212045407","url":null,"abstract":"<p><strong>Aims: </strong>The antihypertensive activity of <i>Daphne gnidium</i> was tested.</p><p><strong>Background: </strong><i>Daphne gnidium</i> (Thymelaeaceae) is used against hypertension.</p><p><strong>Objective: </strong>The antihypertensive effect of <i>Daphne gnidium</i> was evaluated in this study.</p><p><strong>Methods: </strong>The effect of <i>Daphne gnidium</i> aqueous extract (DGAE, 100 and 180 mg/kg) on blood pressure was evaluated in rats. In addition, the vasorelaxant effect of this extract was also tested.</p><p><strong>Results: </strong>DGAE lowered blood pressure in hypertensive rats and exhibited vasorelaxant activity. In addition, cumulative concentrations of DGAE induced vasodilatation through receptoractivated calcium channels (ROCCs) without affecting ACE-2.</p><p><strong>Conclusion: </strong>The aqueous extract of <i>Daphne gnidium</i> exhibits antihypertensive activity and induces vasodilatation via the inhibition of Ca<sup>2+</sup> entry.</p>","PeriodicalId":93924,"journal":{"name":"Cardiovascular & hematological agents in medicinal chemistry","volume":" ","pages":"432-440"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139567713","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Genetic Underpinnings of Pulmonary Fibrosis: An Overview. 肺纤维化的遗传基础:概述。
Pub Date : 2024-01-01 DOI: 10.2174/0118715257261006231207113809
Sushweta Mahalanobish, Sumit Ghosh, Parames C Sil

Introduction: Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive disorder, in which genetic and environmental factors are involved in disease onset. Although, by definition, the disease is considered idiopathic in nature, evidence-based studies have indicated familial cases of pulmonary fibrosis, in which genetic factors contribute to IPF pathogenesis.

Methods: Both common as well as rare genetic variants are associated with sporadic as well as familial forms of IPF. Although clinical inferences of the genetic association have still not been explored properly, observation-based studies have found a genotypic influence on disease development and outcome.

Results: Based on genetic studies, individuals with a risk of IPF can be easily identified and can be classified more precisely. Identification of genetic variants also helps to develop more effective therapeutic approaches.

Conclusion: Further comprehensive research is needed to get a blueprint of IPF pathogenesis. The rapidly evolving field of genetic engineering and molecular biology, along with the bioinformatics approach, will possibly explore a new horizon very soon to achieve this goal.

简介特发性肺纤维化(IPF)是一种慢性进行性疾病,发病与遗传和环境因素有关。虽然根据定义,该病属于特发性疾病,但循证研究表明,在家族性肺纤维化病例中,遗传因素是导致 IPF 发病的原因之一:方法:常见和罕见的遗传变异均与散发性和家族性 IPF 有关。方法:常见和罕见的遗传变异均与散发性和家族性 IPF 有关。虽然遗传关联的临床推论尚未得到充分探讨,但基于观察的研究发现,基因型对疾病的发展和预后有影响:结果:基于基因研究,可以很容易地识别出有患 IPF 风险的个体,并对其进行更精确的分类。鉴定基因变异也有助于开发更有效的治疗方法:要获得 IPF 发病机制的蓝图,还需要进一步的综合研究。快速发展的基因工程和分子生物学领域,以及生物信息学方法,可能很快就会为实现这一目标开拓出一片新天地。
{"title":"Genetic Underpinnings of Pulmonary Fibrosis: An Overview.","authors":"Sushweta Mahalanobish, Sumit Ghosh, Parames C Sil","doi":"10.2174/0118715257261006231207113809","DOIUrl":"10.2174/0118715257261006231207113809","url":null,"abstract":"<p><strong>Introduction: </strong>Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive disorder, in which genetic and environmental factors are involved in disease onset. Although, by definition, the disease is considered idiopathic in nature, evidence-based studies have indicated familial cases of pulmonary fibrosis, in which genetic factors contribute to IPF pathogenesis.</p><p><strong>Methods: </strong>Both common as well as rare genetic variants are associated with sporadic as well as familial forms of IPF. Although clinical inferences of the genetic association have still not been explored properly, observation-based studies have found a genotypic influence on disease development and outcome.</p><p><strong>Results: </strong>Based on genetic studies, individuals with a risk of IPF can be easily identified and can be classified more precisely. Identification of genetic variants also helps to develop more effective therapeutic approaches.</p><p><strong>Conclusion: </strong>Further comprehensive research is needed to get a blueprint of IPF pathogenesis. The rapidly evolving field of genetic engineering and molecular biology, along with the bioinformatics approach, will possibly explore a new horizon very soon to achieve this goal.</p>","PeriodicalId":93924,"journal":{"name":"Cardiovascular & hematological agents in medicinal chemistry","volume":" ","pages":"367-374"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139571601","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Green Synthesis of Silver Nanoparticles using Coriandrum sativum and Murraya koenigii Leaf Extract and its Thrombolytic Activity. 利用芫荽和鹅掌楸叶提取物绿色合成银纳米粒子及其溶栓活性
Pub Date : 2024-01-01 DOI: 10.2174/0118715257279159240118050207
Priyanca Pram, Nikita Mishra, Mohanasrinivasan Vaithilingam, Merlyn Keziah Samuel, Maneesha Mohanan, Neeti Kothari, Subathra Devi Chandrasekaran

Background: Plants have been used for ages in traditional medicine, and it is exciting to perceive how recent research has recognized the bioactive compounds liable for their beneficial effects. Green synthesis of metal nanoparticles is a hastily emergent research area in nanotechnology. This study describes the synthesis of silver nanoparticles (AgNPs) using Coriandrum sativum and Murraya koenigii leaf extract and its thrombolytic activity.

Objective: The aim of the study was to determine the clot lysis activity of Coriandrum sativum and Murraya koenigii synthesized silver nanoparticles.

Methods: Leaves of Coriandrum sativum and Murraya koenigii were collected. Methanolic extraction of the plant sample was done through a Soxhlet extractor. The methanolic extract obtained from both the leaves was subjected to GC-MS analysis. The synthesized NPs from leaf extracts were monitored for analysis, where the typical X-ray diffraction pattern and its diffraction peaks were identified. 3D image of the NPs was analysed by Atomic Force Microscopy. The surface charge of nanoparticles was identified by Zeta potential. The Clot lysis activity of Coriandrum sativum and Murraya koenigii synthesized silver nanoparticles were analysed by the modified Holmstorm method.

Results: The thrombolytic property of the methanolic extract of plants Coriandrum sativum showed clot lysis activity at 2.5 mg/mL with 45.99% activity, and Murraya koenigii extract with 66.56% activity. The nanoparticles (Nps) from Coriandrum sativum showed clot lysis activity at 2.5 mg/mL with 58.29% activity, and NPs from Murraya koenigii with 54.04% activity. Coriandrum sativum in GC-MS exhibited 3 peaks, whereas Murraya koenigii extract showed five peaks with notable bioactive compounds.

Conclusion: These NPs were further used for biomedical applications after being fixed by an organic encapsulation agent. The present research reveals the usefulness of Coriandrum sativum and Murraya koenigii for the environmentally friendly manufacture of silver nanoparticles.

背景:植物在传统医学中的应用由来已久,令人兴奋的是,近年来的研究已经认识到了植物中具有生物活性的化合物对人体的益处。金属纳米粒子的绿色合成是纳米技术中一个新兴的研究领域。本研究介绍了利用芫荽和鹅掌楸叶提取物合成银纳米粒子(AgNPs)及其溶栓活性:本研究旨在确定芫荽和墨旱莲合成的银纳米粒子的血栓溶解活性:方法:采集芫荽和墨旱莲的叶子。通过索氏提取器对植物样本进行甲醇提取。对从这两种叶子中提取的甲醇提取物进行气相色谱-质谱分析。对从叶片提取物中合成的 NPs 进行了监测分析,确定了典型的 X 射线衍射图样及其衍射峰。原子力显微镜分析了 NPs 的三维图像。通过 Zeta 电位确定了纳米粒子的表面电荷。用改进的 Holmstorm 法分析了芫荽和鹅掌楸合成的银纳米粒子的溶栓活性:结果:植物芫荽的甲醇提取物在 2.5 毫克/毫升的溶栓活性为 45.99%,而 Murraya koenigii 提取物的溶栓活性为 66.56%。从芫荽中提取的纳米粒子(Nps)在 2.5 毫克/毫升的浓度下具有 58.29% 的凝块溶解活性,而从墨旱莲中提取的纳米粒子则具有 54.04% 的活性。在气相色谱-质谱(GC-MS)中,芫荽显示出 3 个峰值,而九里香提取物则显示出 5 个峰值,其中含有显著的生物活性化合物:这些 NPs 经有机封装剂固定后可进一步用于生物医学应用。本研究揭示了芫荽和九里香在以环境友好型方式制造银纳米粒子方面的用途。
{"title":"Green Synthesis of Silver Nanoparticles using <i>Coriandrum sativum</i> and <i>Murraya koenigii</i> Leaf Extract and its Thrombolytic Activity.","authors":"Priyanca Pram, Nikita Mishra, Mohanasrinivasan Vaithilingam, Merlyn Keziah Samuel, Maneesha Mohanan, Neeti Kothari, Subathra Devi Chandrasekaran","doi":"10.2174/0118715257279159240118050207","DOIUrl":"https://doi.org/10.2174/0118715257279159240118050207","url":null,"abstract":"<p><strong>Background: </strong>Plants have been used for ages in traditional medicine, and it is exciting to perceive how recent research has recognized the bioactive compounds liable for their beneficial effects. Green synthesis of metal nanoparticles is a hastily emergent research area in nanotechnology. This study describes the synthesis of silver nanoparticles (AgNPs) using <i>Coriandrum sativum</i> and <i>Murraya koenigii</i> leaf extract and its thrombolytic activity.</p><p><strong>Objective: </strong>The aim of the study was to determine the clot lysis activity of <i>Coriandrum sativum</i> and <i>Murraya koenigii</i> synthesized silver nanoparticles.</p><p><strong>Methods: </strong>Leaves of <i>Coriandrum sativum</i> and <i>Murraya koenigii</i> were collected. Methanolic extraction of the plant sample was done through a Soxhlet extractor. The methanolic extract obtained from both the leaves was subjected to GC-MS analysis. The synthesized NPs from leaf extracts were monitored for analysis, where the typical X-ray diffraction pattern and its diffraction peaks were identified. 3D image of the NPs was analysed by Atomic Force Microscopy. The surface charge of nanoparticles was identified by Zeta potential. The Clot lysis activity of <i>Coriandrum sativum</i> and <i>Murraya koenigi</i>i synthesized silver nanoparticles were analysed by the modified Holmstorm method.</p><p><strong>Results: </strong>The thrombolytic property of the methanolic extract of plants <i>Coriandrum sativum</i> showed clot lysis activity at 2.5 mg/mL with 45.99% activity, and <i>Murraya koenigii</i> extract with 66.56% activity. The nanoparticles (Nps) from <i>Coriandrum sativum</i> showed clot lysis activity at 2.5 mg/mL with 58.29% activity, and NPs from <i>Murraya koenigii</i> with 54.04% activity. <i>Coriandrum sativum</i> in GC-MS exhibited 3 peaks, whereas <i>Murraya koenigii</i> extract showed five peaks with notable bioactive compounds.</p><p><strong>Conclusion: </strong>These NPs were further used for biomedical applications after being fixed by an organic encapsulation agent. The present research reveals the usefulness of <i>Coriandrum sativum</i> and <i>Murraya koenigii</i> for the environmentally friendly manufacture of silver nanoparticles.</p>","PeriodicalId":93924,"journal":{"name":"Cardiovascular & hematological agents in medicinal chemistry","volume":"22 2","pages":"230-239"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141556141","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Cardiovascular & hematological agents in medicinal chemistry
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1